The first Leap Therapeutics trade was made in Q2 2021.
Since then Ken Griffin bought shares eight more times and sold shares on seven occasions. The investor completely sold their stake between Q3 2024 and Q1 2025.
Avg closing price
Price range
Sold -92.7 Thousand shares
Q1 2025
Avg closing price
$1.15
Price range
$0.31
-
$3.48
Sold 80.0% shares (-371 Thousand shares)
Q4 2024
Avg closing price
$2.97
Price range
$2.29
-
$4.61
Sold 49.5% shares (-455 Thousand shares)
Q3 2024
Avg closing price
$2.36
Price range
$1.69
-
$3.01
Increased shares by 29.1% (+207 Thousand shares)
Q2 2024
Avg closing price
$2.62
Price range
$1.76
-
$3.41
Increased shares by 4.2% (+28.6 Thousand shares)
Q1 2024
Avg closing price
$3.00
Price range
$2.14
-
$4.67
Increased shares by 6.0% (+38.5 Thousand shares)
Q4 2023
Avg closing price
$2.16
Price range
$1.30
-
$4.78
Increased shares by 661.5% (+560 Thousand shares)
Q3 2023
Avg closing price
$2.32
Price range
$1.31
-
$3.38
Sold 19.2% shares (-20.1 Thousand shares)
Q2 2023
Avg closing price
$46.08
Price range
$3.05
-
$93.32
Increased shares by 142.6% (+61.5 Thousand shares)
Q1 2023
Avg closing price
$52.47
Price range
$29.01
-
$71.91
Increased shares by 185.7% (+28 Thousand shares)
Q4 2022
Avg closing price
$66.87
Price range
$42.01
-
$91.80
Sold 3.4% shares (-524 shares)
Q3 2022
Avg closing price
$121.48
Price range
$88.00
-
$175.00
Sold 78.9% shares (-58.3 Thousand shares)
Q2 2022
Avg closing price
$129.38
Price range
$96.02
-
$191.00
Increased shares by 496.1% (+61.5 Thousand shares)
Q1 2022
Avg closing price
$213.82
Price range
$160.00
-
$335.00
Increased shares by 453.1% (+10.2 Thousand shares)
Q4 2021